Estrogen Patch for COVID-19 Symptoms

COVID Clinical Trial

Official title:

Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04359329
• Other study ID #: SBU-EstrogenPatch-COVID19
• Status: Terminated
• Phase: Phase 2
• Start date: April 20, 2020
• Est. completion date: July 30, 2020

Study information

• Verified date: April 2020
• Source: Stony Brook University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out if estrogen, a female sex hormone, given as a patch placed on skin of COVID19 positive or presumptive positive patients for 7 days can reduce the severity of COVID19 symptoms compared to regular care.

This study has two study groups. One group will receive the study drug, a single-use Climara 25cm2 estrogen patch. The other group will receive standard of care.

Participants will be asked questions about their symptoms for up 6 times in up to 45 days.

Description:

As the COVID19 pandemic has spread, it has been observed that adult men of all ages and older women are at higher risk of developing serious complications from infection with the virus. Animal model studies of SARS suggest that the age and sex difference in COVID19 symptom severity may be due to protective and acute actions of the female sex hormone estrogen. Animal and human studies support immune modulating effects of estrogen that are acute acting in viral infections and wound repair processes that may reduce the damaging effects of the virus on the lung and symptom severity.

Our hypothesis is that a short 7 day course of estradiol delivered in a transdermal patch applied to the upper buttock in COVID19+ or presumptive positive patients will be safe and will reduce symptom severity in adult men and older women when given prior to intubation. COVID19+ and presumptive positive patients not requiring intubation will be enrolled to the study and randomized to receive an estrogen patch or standard of care. Patients will be followed up at day 1, 7, 14 and 28 for clinical symptoms and disease outcomes.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: July 30, 2020
• Est. primary completion date: July 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male = 18 years of age or female = 55 years of age

• Documentation of COVID19 positivity or the presence of one or more of the following new onset (<7 days) clinical features defining presumptive COVID19

1. fever of >100.5°F or 38°C

2. shortness of breath

3. cough

4. radiologic evidence of pneumonia

• Able to provide informed consent

• Able to be contacted by telephone for follow-up

Exclusion Criteria:

• Currently receiving estrogen based hormonal therapy

• Abnormal genital bleeding

• Protein C or Protein S deficiency

• Pre-existing liver impairment (e.g. Hepatitis C, cirrhosis)

• History of anaphylactic reaction or angioedema with Climara

• Receiving lamotrigine therapy

• Subjects with known past diagnosis of estrogen receptor positive breast cancer or endometrial cancer

• Subjects with severe hypoxia at risk for acute intubation in ED

• History of stroke

• Any history of thromboembolic event including deep vein thrombosis or pulmonary emboli

• Current use of St. John's Wort

• Males on testosterone

• History of myocardial infarction, cardiac stents, or active angina

Related Conditions & MeSH terms

• COVID
• COVID-19

Intervention

Drug:
• Estradiol patch
Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin

Locations

Country	Name	City	State
United States	Stony Brook University Hospital	Stony Brook	New York

Sponsors (1)

Lead Sponsor	Collaborator
Sharon Nachman

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Hospitalization	Admission to hospital due to COVID-19 symptoms	30 days
Primary	Rate of Transfer to Intensive Care Unit	Occurrence of admission to ICU due to COVID-19 symptoms	30 days
Primary	Rate of Intubation	Occurrence of intubation	30 days
Primary	Rate of Death	Occurrence of death from COVID-19	30 days